{"entity":{"id":"nct01200485","kind":"trial","name":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2","aka":[],"tldr":"A phase 2 trial of Rasburicase in Leukaemia, run by M.D. Anderson Cancer Center, completed.","summary":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 is a phase 2 interventional study registered as NCT01200485 by M.D. Anderson Cancer Center, with 55 participants recorded, started 2011-04 and reaching its primary completion in 2016-07. Interventions recorded: Rasburicase, Allopurinol. Conditions recorded: Leukemia, Lymphoma.\n\nLinked to the drug Rasburicase because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01200485","url":"https://clinicaltrials.gov/study/NCT01200485"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["rasburicase"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01200485","phase":"2","setting":"A Randomized Phase 2 Study to Evaluate the Efficacy of Rasburicase in Patients at Risk for TLS During Two Cycles of Chemotherapy","sponsor":"M.D. Anderson Cancer Center","enrolled":55,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01200485/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"rasburicase","kind":"drug","name":"Rasburicase","route":"/drugs/rasburicase/"}]}}